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Abstract 
Background: Genetic studies of schizophrenia have implicated numerous risk loci including 
several copy number variants (CNVs) of large effect and hundreds of loci of small effect. In only 
a few cases has a specific gene been clearly identified. Rare CNVs affecting a single gene offer a 
potential avenue to discovering schizophrenia risk genes.  
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Methods: CNVs were generated from exome-sequencing of 4,913 schizophrenia cases and 6,188 
controls from Sweden. We integrated multiple CNV calling methods (XHMM and ExomeDepth) 
to expand our set of single-gene CNVs and leveraged two different approaches for validating these 
variants (qPCR and Nanostring). 
Results: We found a significant excess of all rare CNVs (deletions p=0.0004, duplications 
p=0.0006) and single-gene CNVs (deletions p=0.04, duplications p=0.03) in schizophrenia cases 
compared to controls. An expanded set of CNVs generated from integrating multiple approaches 
showed a significant burden of deletions in 11/21 gene-sets previously implicated in schizophrenia 
and across all genes in those sets (p=0.008), although no tests survived correction.  We performed 
an extensive validation of all deletions in the significant set of voltage-gated calcium channels 
among CNVs called from both exome-sequencing and genotyping arrays. In total, 4 exonic, single-
gene deletions validated in cases and none in controls (p=0.039), of which all were identified by 
exome-sequencing.  
Conclusions: These results point to the potential contribution of single-gene CNVs to 
schizophrenia, that the utility of exome-sequencing for CNV calling has yet to be maximized and 
single-gene CNVs should be included in gene focused studies using other classes of variation. 
 
Introduction 
Schizophrenia (SCZ) is a heritable psychiatric disorder that causes substantial morbidity, 
mortality, and personal and societal costs(1–4). Identifying genetic variation influencing risk will 
improve our biological understanding of SCZ. Copy number variants (CNVs) are appealing as 
they directly alter gene dosage providing an interpretable effect on gene function. SCZ cases carry 
a burden of large and rare CNVs (>100 kb and <1%)(5,6) and multiple rare recurrent CNVs with 
 3 
substantial effects on risk (genotypic relative risks 4-20) have been identified (e.g., 16p11.2 and 
22q11.21)(6–11). Most of these known CNVs are megabase-sized and affect the dosages of many 
genes, but if specific genes contributing to risk could be identified it would aid our understanding 
of the neurobiology of the disorder. Thus far, only a few individual genes from genetic studies of 
CNVs and SNVs have been implicated: NRXN1(12), TOP3B(13), RBM12(14) and SETD1A(15), 
all of which provided novel insights into SCZ pathophysiology. Therefore, gene-focused CNV 
evaluation in large samples with high resolution capture is needed.  
The majority of CNVs have a small genomic footprint(16–19) and, due to technological 
limitations or cost, their contribution to SCZ remains unknown(20). Commercial microarrays are 
limited in resolution by probe density and are largely incapable of detecting CNVs below 10 kb 
while also having low specificity for CNVs between 10 and 100 kb(21). CNV detection from 
whole genome sequencing offers a substantial improvement, but remains expensive and is 
currently infeasible for large samples. Whole exome sequencing (WES) can be used to identify 
CNVs impacting exons(22). These data, while noisy from dependence on read depth and lacking 
exact breakpoints from the discrete nature of exons, can be used to identify smaller CNVs affecting 
single genes that may be more interpretable in their contribution to SCZ risk.  
Here, we performed a comprehensive analysis of CNVs from WES data in the Swedish 
Schizophrenia Study of 4,978 schizophrenia cases and 6,256 controls(23). Our goals were to 
evaluate the impact of single-gene CNVs on SCZ risk, and to discover copy number changes in 
specific genes that could lead to improved mechanistic understanding of SCZ risk. All samples 
also have GWAS genotyping arrays and Illumina exome arrays(24,25) providing additional data 
to follow up and validate CNVs.  
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Methods 
Sample description 
We extracted DNA from venous blood samples from 11,234 Swedish participants (4,978 SCZ 
cases, 6,256 controls, mean age at sample collection: 55 years). An additional 1,172 samples were 
included in generating and cleaning exome-sequencing CNVs to improve estimates of copy 
number and frequency but were removed before analyses (total N: 12,384). All procedures were 
approved by ethical committees in Sweden and the US, and all subjects provided informed written 
consent. Genomic investigation of each subject was done using independent technologies 
including GWAS genotyping(24), exome array genotyping(20), and exome sequencing(23,26). 
Genotyping and sequencing were conducted at the Broad Institute. Rare CNVs from GWAS arrays 
and exome genotyping arrays had been previously generated(20,25), and is briefly described in the 
supplementary material. Exome-sequencing based CNVs were generated for this analysis and have 
not previously been reported. Individuals already known to be carrying large CNV were included 
in all analyses. All genomic locations are given in NCBI build 37/UCSC hg19 coordinates. 
 
CNV calling and QC using XHMM 
We ran XHMM (eXome-Hidden Markov Model) as previously described(22,27), including 
calculating mean per-base coverage across 189,894 targets (sequences designed for capture, 
predominantly exons) using GATK DepthOfCoverage. A total of 14,555 targets were excluded 
before CNV calling due to: mean sequencing depth <10x, low complexity sequence (as defined by 
RepeatMasker) in >25% of its span, GC content <10% or >90%, and spanning <10 bp or >10 kb. 
The resulting sample-by-target read depth matrix was scaled by mean-centering the targets, after 
which principal component analysis (PCA) of the matrix was performed. To normalize the data, 
 5 
the top 109 principal components (those with variance >70% of the mean variance across all 
components) were removed from the data to account for systematic biases at the target- or sample-
level, such as GC content or sequencing batch effects. Additional targets (n=37) were removed if 
variance in read depth remained high after normalization (standard deviation >50). CNVs were 
called using the Viterbi hidden Markov model (HMM) with default XHMM parameters, and 
XHMM CNV quality scores (SQ) were calculated using the forward-backward HMM. For any 
CNV detected in at least one individual, we statistically genotyped all samples using the same 
XHMM quality scores and outputted as a single VCF. Twenty-two samples failed CNV calling 
due to low overall read depth, A total of 175,303 targets were used to call CNVs across 12,384 
samples after all filtering.  CNVs from sex chromosomes would be inaccurately called since males 
and females were run together and so were removed from analyses. 
There were 494,403 autosomal CNVs called by XHMM before any filtering. We removed 
115 individuals (56 cases, 59 controls) with > 3 standard deviations from the mean in total number 
of CNVs (71.5) or total genomic content affected by CNVs (6,529 kb). After sample outlier 
removal, 484,940 CNV (SQ > 0) were used to develop a frequency filter, and we retained only 
CNVs present in less than 1% of individuals (<0.5% minor allele frequency). To account for the 
discrete nature of exons, each target was numbered sequentially based on genomic coordinates and 
frequency filtering was done using the sequential target information before mapping targets to 
genomic positions. After frequency filtering, there were 51,812 CNVs with a per individual mean 
of 4.3 ranging from 1-107. After quality filtering (SQ ≥ 60), 14,243 CNVs remained (we refer to 
this dataset going forward as the “exome QC” dataset). The median CNV length was 22,991bp 
and 77% (n=10,950) were below 100kb which is a typical cutoff for array-based CNVs. We note, 
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however, that the lengths of CNVs generated from exome-sequencing are often inaccurate due to 
the discrete nature in which breakpoints are determined.  
 
Expanded single-gene CNV dataset integrating XHMM and ExomeDepth 
Increasing XHMM quality scores (SQ) disproportionately removes shorter CNVs. In an effort to 
quantify the proportion of shorter CNVs with lower quality scores that are true, we used exome-
sequencing data from 624 trios(28) and calculated transmission as a function of quality score and 
minimum number of targets required per CNV. These data were processed as described above. We 
focused on rare CNVs (< 0.1%) to avoid counting transmissions arbitrarily. At default filtering 
thresholds (SQ ≥ 60, >= 3 exons) we calculated a transmission rate of 0.42 (64 maternal CNVs, 
26 transmitted; 71 paternal CNVs, 30 transmitted). CNVs having a single supporting exon and no 
minimum SQ (i.e. all CNVs) were substantially more frequent but had reduced transmission rate 
of 0.114 (449 maternal CNVs, 55 transmitted; 575 paternal CNVs, 62 transmitted). However, this 
transmission rate suggests that potentially 20+% of these “low quality” events may be real. As a 
method to retain the true shorter CNVs while removing as many of the false positive CNVs as 
possible we required additional support from an independent approach ExomeDepth(29). Briefly, 
ExomeDepth selects a reference set of individuals having similar sequencing properties 
independently for CNV inference of each sample. We called CNVs within experimental plates of 
96 individuals that were processed and sequenced at the same time in order to provide the most 
comparable reference set for each sample and reduce batch effects. In total, we called CNVs for 
12,313 samples totaling 1,915,300 CNV with a mean of 155.5 per individual and ranging from 1-
811.  
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We retained all XHMM calls with SQ ≥ 60 and any CNV called by both ExomeDepth and XHMM 
regardless of quality score (referred to as the “expanded exome” dataset). For comparison, 92% of 
calls from the exome QC dataset were called by ExomeDepth whereas only 20% of CNVs 
affecting a single exon and low SQ (< 30) were called across both methods. In total, the expanded 
exome dataset had 24,843 CNVs (10,600 added to exome QC). To further assess quality, we 
compared the additional CNVs to a high confident set of CNVs (>100kb) from genotyping arrays 
of the same individuals(25). While the vast majority of these calls (90%, 3,254 out of 3,597) are 
identified in our exome QC dataset, there are still 343 that that are called by XHMM but that do 
not surpass the filtering threshold. Only 28% (10,600/37,569) of the possible XHMM calls were 
added to our expanded exome dataset yet 88% (300/343) of the remaining high-quality genotyping 
CNVs were included. Using the union of the two approaches allows us to expand our set of shorter 
CNVs while retaining only those with the most support.  
 
CNV burden and association analyses 
We performed burden and association analyses using Plink(30), employing empirical permutation 
(n=10,000) of case/control label where permutation was performed within sequencing batch to 
account for any batch effects. CNVs were considered to affect a gene if there was any overlap of 
the genomic coordinates of the CNVs and the gene. For gene-set tests, we used a regression 
framework built into Plink(31) that tests whether cases carry more CNVs in the set of genes 
compared to all genes after covarying for number and amount of CNVs.  
 
 8 
Incorporating CNVs from previously run genotyping arrays of the same individuals 
To maximize the sensitivity to detect gene/exon level CNVs, we constructed a union call set by 
combining the data from GWAS array, exome array, and our expanded exome CNV dataset. We 
first created a database of all non-redundant CNVs, where, for each CNV record, we indicated (1) 
how many platform(s) had identified the CNV; (2) which specific platform(s) had identified the 
CNV; (3) the coordinates of CNV from each platform. We considered two CNVs redundant if they 
had the same direction of the copy number change and they overlapped more than 50% of their 
lengths. Details for this “exome plus array” dataset are described in supplemental materials 
(Tables S3-S4, Figure S2).  
 
Validation of CNV 
We attempted validation of 55 deletions from the exome plus array dataset that affected any 
calcium channel gene (N = 26 genes) using a combination of both quantitative PCR (qPCR) and 
NanoString nCounter technology. First, qPCR was used to verify 6 CNVs detected in calcium 
channel genes CACNA2D3, CACNA1B, CACNA2D4 and CACNG2 (Table S5). Several 
predesigned TaqMan Copy Number Assays were run in quadruplicate along with the internal 
RNase P Copy Number Reference Assay according to manufacturer’s instructions (Applied 
Biosystems, Foster City, CA). Briefly, 20 µl reactions containing 1 µl DNA (5 ng), 10 µl of 2X 
Taqman Genotyping Master Mix, 1 µl of one target CNV assay and 1 µl of RNase P reference 
assay were mixed. All qPCR reactions were run on a Life Technologies StepOnePlus machine 
with the following thermal cycling conditions: 95°C for 10 min, followed by 40 cycles of 95°C for 
15 s and 60°C for 1 min. Samples included all suspected CNV carriers for each gene, regardless 
of case or control status, as well as four presumed two-copy controls per gene.  
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Second, for a larger scale validation, we used Nanostring nCounter technology. For each 
CNV, two probes were designed and analyses were performed according to manufacturer 
instructions. In brief, a spike-in plasmid of known amount was used to control for variability in 
DNA quantity across all samples and additional controls ensured optimal hybridization and 
purification efficiency. After hybridization and removal of excess probes, the probe/target 
complexes were aligned and immobilized in the nCounter Cartridge, and imaged in the nCounter 
Digital Analyzer for detection of CNVs. In a previous study, we examined nCounter’s CNV calling 
accuracy by testing 37 known CNVs in 384 samples and found 97% concordance. We were able 
to successfully attempt validation for 48 of the 55 deletions. 
 
Results 
 
Exome-sequencing CNVs demonstrate high concordance with genotyping array based CNVs 
while contributing substantial numbers of novel variants  
We generated CNVs using XHMM for 4,913 SCZ cases and 6,188 controls resulting in a total of 
14,243 rare (present in less than 1% of individuals) and high quality (SQ ≥ 60) CNVs (“exome QC 
dataset”). In a comparison to previously published CNVs from genotyping arrays on these 
individuals(25) (see Supplementary Methods) we identified 78% of the array-based CNVs in the 
exome QC dataset. More interestingly, 75% of the exome QC calls were not seen in the array-
based call set. Individuals carried, on average, 2.2 times more CNVs in the exome QC dataset than 
in the array-based call set (1.28 versus 0.59 CNVs). This comparison is described in more 
detail(22). Specific to this work, 53% of exome QC CNVs overlapped a single protein coding gene 
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(94% had length < 100kb) and, of those, only 12.6% were included in the previous work on this 
sample leaving 87.4% or 6,622 single-gene CNVs to be analyzed for the first time here. 
 
Significant burden of exome-sequencing based CNVs in SCZ including among single-gene 
CNVs 
We first assessed the burden of all CNVs in the exome QC dataset to SCZ. Utilizing empirical 
permutation of case/control label (see Methods) we identified a significant increase in the numbers 
of deletions (case rate: 0.56, control rate: 0.51, p = 0.0004) and duplications (case rate: 0.78, 
control rate: 0.72, p = 0.0006) in SCZ cases compared to controls as seen previously in this 
sample(25). To identify the contribution of the novel CNVs in our exome QC dataset, we 
performed the same burden test using only CNVs new to this analysis and not called by arrays in 
previous work. Here, we again saw significant burden in cases for both deletions (case rate: 0.48, 
control rate: 0.45, p = 0.0114) and duplications (case rate: 0.56, control rate: 0.51, p = 0.0003). 
The exome QC CNVs are substantially shorter and therefore more likely to affect only a single 
gene. We tested whether burden of CNVs was primarily driven by larger events affecting multiple 
genes or if single-gene CNVs were contributing. We identified a significant but modest burden of 
single-gene deletions (case rate: 0.36, control rate: 0.34, p = 0.0395) and duplications (case rate: 
0.34, control rate: 0.32, p = 0.0332) in SCZ cases compared to controls (Figure 1, Table 1). These 
results were not driven by CNV length in deletions (p < 100kb = 0.071, p > 100kb = 0.072) or 
duplications (p < 100kb = 0.053, p > 100kb = 0.181). 
 
Expanding the set of potential single-gene CNVs and testing for excess in specific genes 
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We next sought to test whether CNVs could implicate specific genes using both the exome QC 
dataset as well as an expanded exome dataset created to increase the proportion of shorter CNVs 
which our QC filters were disproportionately removing (see Methods). Briefly, we integrated 
CNVs called from both XHMM and ExomeDepth(29) retaining CNVs if detected by both methods 
regardless of XHMM quality scores or if detected only by XHMM at our previous filtering 
threshold (SQ ≥ 60). In total, our “expanded exome dataset” included an additional 10,600 CNVs 
(total: 24,843) substantially increasing the proportion of shorter events (Figure S1). Individual 
genes were tested for excess of deletions or duplications using empirical permutation. After 10,000 
permutations in our exome QC dataset, 21 genes were significantly enriched for duplications and 
40 genes were significantly enriched for deletions in cases compared to controls after multiple test 
correction. All significant genes fell into two genomic regions of already known large SCZ risk 
CNVs, 16p11.2 (duplications) and 22q11.2 (deletions) leaving no novel genes identified (Figure 
2). Finally, using our expanded exome dataset we again tested for enrichment of deletions and 
duplications in specific genes. No gene was significant after correction with the most significant 
genes again being driven by the larger 16p11.2 or 22q11.2 CNVs.  
 
Testing contribution of only single-gene CNVs to previously implicated SCZ gene sets 
In the absence of any novel genes being identified above, we tested whether single-gene CNVs 
were enriched among previously implicated gene sets. In the expanded exome dataset, there were 
14,091 CNVs affecting only a single protein-coding gene (7,423 deletions, 6,668 duplications) and 
7,703 affecting multiple genes (2,443 deletions, 5,260 duplications). The sets tested included genes 
previously implicated in other SCZ studies (GWAS loci(32), de novo variants(33), CNV 
regions(6)), synaptic function(5) (ARC, mGluR5, NMDAR, PSD95), calcium channels(26) 
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(CAV2, Voltage-gated), secondary sets (FMRP targets(23,26), ASD/DD/ID de novo(33), essential 
genes(34), constrained genes(35), RBFOX related genes(23) and antipsychotic targets(36)). The 
combined set of genes across all sets (n = 8,970) showed significant excess in cases for single-
gene deletions (p = 0.008) but not duplications (p=0.186). We identified nominally significant 
enrichment of single-gene deletions in over half (11 out of 21) of the sets (Table 2), however no 
gene set surpassed a Bonferroni corrected p-value of 0.0005 for the 88 tests performed. For 
comparison, multi-gene deletions also showed nominally significant enrichment in 11 of the 21 
sets, including 6 that surpassed Bonferroni correction (all genes, DD de novo, ID de novo, 
constrained, essential and SCZ deletion regions). Multi-gene duplications were significantly 
enriched in 7 of the 11 sets but none survived correction including all genes (p=0.007). 
 
Broad scale exploration of CNVs in calcium channel genes combining both the expanded 
exome dataset and array-based calls 
Among the most significant gene sets, we selected voltage-gated calcium channels for a full-scale 
validation since it represented an approachable number of CNVs to validate comprehensively and 
had significant prior supporting literature. Across the 26 genes, we identified 6 deletions in cases 
and 0 in controls from our expanded exome dataset (Figure 3). Since validation with an 
independent technology is considered the gold standard for CNV work, we attempted to validate 
these deletions using quantitative PCR (qPCR). Four of the deletions validated, two identical single 
exon deletions in CACNA2D3 did not validate (these two did not surpass filtering thresholds to be 
included in the exome QC dataset). Since we had additional CNV data from genotyping arrays, 
we wanted to validate a larger set of calcium channel deletions to more comprehensively catalog 
the contribution of deletions in these genes to risk of SCZ in this sample. We identified a set of 
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deletions across our exome plus array dataset (see Methods and Supplementary Methods) 
overlapping any voltage-gated calcium gene. In total, we identified 55 deletions in 55 different 
samples of which 48 could be tested using NanoString nCounter technology (see Methods). Of 
these, 34 were located over three common, intronic copy number polymorphisms (all of which 
validated). Of the 21-remaining rare-variant calls, 6 validated (see Table 3). The low validation 
rate is representative of our decision to take all CNVs with limited evidence and not filter on 
confidence. Nearly all of the CNVs that did not validate were low quality calls from the genotyping 
arrays. Four of the validated deletions were single-gene, in cases and identified in the expanded 
exome dataset. The remaining two validated deletions were a non-exonic deletion and a multi-
gene deletion in a control identified from genotyping arrays. After validation, we were left with 4 
single-gene deletions in cases and 0 in controls (p = 0.039). 
Discussion 
 
This study represents an evaluation of smaller CNVs in a large SCZ sample. We found that, 
independent of larger events, deletions of single genes may contribute to schizophrenia risk 
through a number of biological pathways previously identified for SCZ.  In particular, we identify 
and validate a small number of deletions in voltage-gated calcium channels that are enriched in 
SCZ cases compared to controls. We also demonstrate the utility of exome-sequencing to identify 
shorter, single-gene CNVs and the potential to improve the resolution of those events through 
combining multiple methods for further study. 
To date, the contribution of CNVs to SCZ risk has been predominantly from large (>100kb) 
and rare CNVs both in specific loci and in aggregate across the genome(6). The ability to determine 
the contribution from shorter CNVs has been both technologically limited by the use of genotyping 
arrays but also biologically up for debate as few single genes have been implicated in SCZ risk 
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and nearly all risk increasing CNVs affect many genes. Here, we point to the potential contribution 
of single-gene CNVs to risk for SCZ. This contribution can be identified both genome-wide and 
within genes having been previously implicated from other studies of genetic variation including 
synaptic genes, genes having de novo mutations in SCZ, DD, ASD or ID, conserved genes and 
gene targets of antipsychotics. In comparison, multi-gene CNVs showed more significant 
enrichment among these sets including 6 surpassing correction but the majority of significant sets 
were shared between single-gene and multi-gene CNVs. Many of these gene sets were discovered 
from large CNV analyses making these results already known. Also, many of the large CNVs 
implicated in SCZ also contribute to other related phenotypes such as DD and ID. More 
interestingly, there were 4 sets that showed significant enrichment only in single-gene CNVs that 
included calcium channels and SCZ LoF de novo variants pointing to potential examples of 
variants of large effect on SCZ risk that have not yet been seen in the larger CNVs. This work 
points to a confluence of evidence that these gene sets are relevant for schizophrenia biology. We 
did not identify any specific gene that was significantly associated after correction for multiple 
testing. Given other studies of rare variation in complex diseases with similar sample sizes, this is 
not surprising(25) but our results suggest that combining CNV data with SNV data could improve 
power to implicate specific genes and robust approaches to combine these classes of variation are 
needed. For these approaches, leveraging knowledge of how intolerant a gene is to variation, 
thereby weighting variants by their potential impact may also improve discovery. Further, while 
the overall contribution of CNVs to SCZ risk is modest and the contribution from single-gene 
CNVs is even less, the addition of CNV burden to measures of individual risk such as polygenic 
risk scores could offer improvements in risk stratification and should be fully assessed. 
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Calcium channel genes have been implicated in psychiatric disease risk, including in SCZ 
for many years. Studies to date from the genetics of SCZ have implicated both particular loci and 
the geneset as a whole. Here, we show an excess of single-gene CNVs in calcium channels among 
SCZ patients that remains after qPCR validation. Given the importance of this gene set and the 
relative size, we also performed a larger validation of deletions using a higher throughput method 
that again confirmed 4 qPCR validated single-gene deletions in cases as well as validating several 
common CNVs, one >2Mb deletion in a control and one deletion that did not overlap an exon in a 
control. Our results suggest that deleting a single calcium channel gene may be relevant for SCZ 
risk however substantially more data will be required to confirm this finding. 
We show that exome-sequencing can identify a substantial number of novel CNVs that are 
not captured by genotyping arrays and are predominantly affecting only a single gene. Further, 
this work points to the existence of many real single-gene CNVs that are filtered out by default 
filtering criteria and by combining multiple currently existing approaches we can capture an 
expanded set of true calls. While exome-sequencing can substantially improve resolution of CNV 
calling it is not without its weaknesses and limitations that become even clearer as CNVs get 
smaller. Whole-genome sequencing will offer the best resolution to confidently identify single-
gene CNVs but is still prohibitively expensive for most labs and hundreds of thousands of exome 
sequences currently exist, and many more are being generated, making CNV calling from exome-
sequencing still important. We believe there are opportunities to improve the ability to call shorter 
CNVs from exome-sequencing that are more sophisticated than merging call sets from multiple 
approaches and there is continued effort in this area that we anticipate will provide additional value 
to CNV calling from exome-sequencing. 
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Here, we demonstrate a potential role for single-gene deletions to contribute to SCZ risk through 
similar pathways as previously implicated. We perform a comprehensive validation of deletions 
in voltage-gated calcium channel genes and show an enrichment of these deletions in SCZ cases 
compared to controls. Finally, we demonstrate further utility for CNV generated from exome-
sequencing and the ability to improve resolution of shorter events which could improve our ability 
to identify biological causes of diseases like SCZ. 
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Figure Legends 
Figure 1. Burden tests across all high confident exome-seq CNVs (all), those not previously 
analyzed from genotyped arrays (new), those previously published (published) and only those 
CNVs affecting a single protein coding gene (single-gene). Deletions are in red (left) and 
duplications are in blue (right). Significance is represented as p < 0.05 (*), p < 0.001 (**). 
 
Figure 2. Gene-based Manhattan plot of duplications in blue (top) and deletions in red (bottom). 
Genes in most significant regions are labeled by known CNVs in that region. 
 
Figure 3. Gene model plots for each of the 4 genes and 6 deletions identified in voltage-gated 
calcium channel genes. Upper grey bars portray deletion in genomic space, below that is the gene 
model in genomic space. The bottom bars represent the exons as transcribed, red indicates exons 
that were deleted. All deletions replicated except the two shown in panel B. 
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Table 1. CNV burden results stratified by CNV type (deletions, duplications), number of genes 
affected (all, single gene or multiple genes) and whether the CNV was unique to our exome-
sequencing call set or was identified in previous array-based CNV work. Bolded p-values are less 
than 0.05. 
 
 
 
 
 
 
 
 
 
 
 
  Deletions  Duplications 
   N Case rate Control rate P   N Case rate Control rate P 
All 
All 5900 0.56 0.51 0.0004   8343 0.78 0.73 0.0006 
New 5101 0.48 0.45 0.0114   5925 0.56 0.51 0.0003 
Previously called by genotyping arrays 799 0.08 0.06 0.0002   2418 0.23 0.21 0.1396 
Single gene 
All 3894 0.36 0.34 0.0395   3680 0.34 0.32 0.0332 
New 3530 0.33 0.31 0.0543  3092 0.29 0.27 0.0162 
Previously called by genotyping arrays 364 0.03 0.03 0.1998   588 0.05 0.05 0.6180 
Multiple genes 
All 1773 0.18 0.14 0.0001   4516 0.42 0.39 0.0030 
New 1339 0.13 0.11 0.0174   2695 0.25 0.23 0.0076 
Previously called by genotyping arrays 434 0.05 0.03 0.0001   1821 0.17 0.16 0.0756 
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Table 2. Geneset CNV results for single-gene and multi-gene CNVs in expanded dataset. Bold 
represents pathways with p-value < 0.05. 
 
 
 
 
 
 
    Single gene CNV Multi gene CNV 
Group Set N genes   P del P  dup P del P  dup 
SCZ sets 
PGC2 SCZ 108 loci 329   0.4199 0.7021 0.6372 0.0260 
SCZ de novo LoF 87  0.0296 0.0911 0.4697 0.6710 
SCZ de novo NS 611  0.2761 0.9024 0.0857 0.5107 
PGC2 16 CNV 175  0.0055 0.9989 0.0451 0.0212 
PGC2 16 CNV (deletions) 78  0.2594 0.9289 0.0001 0.9602 
PGC2 16 CNV (duplications) 111  0.0077 0.5790 0.0757 0.0082 
Synaptic Sets 
ARC 28   1.0000 0.3543 0.4426 0.5778 
mGluR5 39  0.2425 0.8117 0.2168 0.2144 
NMDAR_network 61  0.0335 0.8099 0.0180 0.0243 
PSD-95_(core) 65   0.0697 0.8984 0.0009 0.2630 
Calcium Channel Sets 
CAV2 206   0.0347 0.4065 0.1624 0.4822 
CAV2 Ion 44  0.1738 0.2395 0.3951 0.6500 
Voltage-gated_Calcium_Channel_Genes 26   0.0082 0.2792 0.9953 0.8284 
Secondary Sets 
FMRP-targets 788  0.0205 0.5018 0.0216 0.0123 
ASD de novo 1080  0.0521 0.4664 0.0796 0.1123 
DD de novo 1271  0.0161 0.9660 0.0003 0.1308 
ID de novo 350  0.0898 0.5774 0.0001 0.5938 
Antipsychotic targets 347  0.0268 0.9338 0.0342 0.7322 
Essential genes 3915  0.0622 0.1975 0.0001 0.0987 
Rbfox 2737  0.0058 0.2056 0.0087 0.0200 
LoF intolerant (pLI > 0.9) 3488   0.0163 0.2430 0.0001 0.0041 
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Table 3. List of all rare deletions overlapping the 26 voltage-gated calcium channel genes that 
validated including one that did not overlap an exon and one that was not single-gene. Four of the 
6 single-gene deletions identified in the geneset analyses and in figure 3 validated (CACNA2D3 
did not). 
 
 
  
Status Chr Start Stop Size (bp) Gene Single-gene? Exonic? 
case 9 140866027 141004005 137978 CACNA1B yes yes 
case 9 140846726 141016451 169725 CACNA1B yes yes 
case 12 1949932 1965357 15425 CACNA2D4 yes yes 
case 22 36960396 36960935 539 CACNG2 yes yes 
control 3 54262746 54316431 53685 CACNA2D3 yes no 
control 7 79818265 82072777 2254512 CACNA2D1 no yes 
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